PET/CT for Trop2 ADC Response Evaluation Cancers

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to see how well a specific breast cancer treatment is working. The treatment targets a protein called Trop2 found on some breast cancer cells, using a special medicine called an antibody-drug conjugate (ADC). To check if the treatment is effective, doctors will use a special type of imaging scan called a 68Ga-MY6349 PET/CT. This scan helps them see the cancer’s response to the treatment without needing surgery or other invasive tests. The goal is to find out if these scans can reliably predict how well the therapy is working over time.

Women with metastatic breast cancer (cancer that has spread to other parts of the body) who have already had previous treatments may be eligible to join. To participate, they need to have at least one tumor that can be measured on scans, be generally well enough to undergo treatment and scans, and be willing to have multiple PET/CT scans before and during their treatment. People with severe liver or kidney problems or those expected to live less than three months would not qualify. Participants can expect to receive the Trop2-ADC therapy and have several imaging scans to monitor their cancer’s response in a safe and noninvasive way. This study is currently recruiting, so eligible patients interested in this approach may want to discuss it with their healthcare provider.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - (i) adult patients (aged 18 years or order); (ii) histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports; (iii) presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1; (iv) willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy; (v) Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; (vi) Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • (i) Evidence of significantly impaired hepatic or renal function; (ii) Estimated life expectancy of less than 3 months.